Mexico City, April 27th, 2012
GENOMMA LAB INTERNACIONAL SECURES COMMITTED FINANCING TO ACQUIRE PRESTIGE BRANDS HOLDINGSG e n o m m a L a b I n t e r n a c i o n a l , S . A . B . d e C . V . ("Genomma") (BMV: LAB.B.) reiterated today that it has secured committed financing, subject to customary conditions, from BofA Merrill Lynch and Jefferies Finance LLC to acquire all of the outstanding shares of Prestige Brands Holdings, Inc. ("Prestige") (NYSE: PBH) common stock for $16.60 per share in cash.
Genomma is filing the executed commitment letters with the U.S. Securities and Exchange Commission and the Comisión Nacional Bancaria y de Valores (Mexican National Banking and Securities Commission) and they will be publicly available on Monday, April 30, 2012.
Genomma once again demonstrates that financing for the transaction was never an issue and it has satisfied Prestige's conditions. Genomma once again emphasizes that it is fully prepared at any time to meet with representatives of Prestige to negotiate a mutually acceptable transaction.
Company DescriptionGenomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico, offering more than 78 brands, many of which are leaders in their product categories. Genomma has extensive in-house product development capabilities that it uses to develop trusted and established brands. Genomma's top-selling brands occupy a "top-of-mind" position for many consumers. These top- selling brands are supported by a broad portfolio of products which largely target large, high- growth over-the-counter pharmaceutical and personal care markets. For more information, visit
www.genommalab.com.
Contact:
Investor Relations In New York: Grayling USA, Lucía Domville
Tel: +52 (55) 5081 0000 Ext. 5106 Tel: +1 (646) 284-9416
E-mail: inversion@genommalab.comE-mail: genommalab@grayling.com
Forward-looking Statements
This communication may contain certain forward-looking
statements and information relating to Genomma that reflect
the current views and/or expectations of Genomma and its
management with respect to its performance, business and
future events. Forward looking statements include, without
limitation, any statement that may predict, forecast,
indicate or imply future results, performance or
achievements, and may contain words like "believe,"
"anticipate," "expect,"
"envisages," "will likely result," or any
other words or phrases of similar meaning. Such statements
are subject to a number of risks, uncertainties and
assumptions. These risks and uncertainties include, but are
not limited to, the possibility that Genomma will not pursue
a transaction with Prestige, the timing to consummate a
potential transaction between Genomma and Prestige, the
ability and timing to obtain required regulatory approvals,
Genomma's ability to realize the synergies contemplated
by a potential transaction and Genomma's ability to
promptly and effectively integrate the businesses of Prestige
and Genomma. We caution you that a number of important
factors could cause actual results to differ materially from
the plans, objectives, expectations, estimates and intentions
expressed in this communication and in oral statements made
by authorized officers of Genomma. Readers are cautioned not
to place undue reliance on these forward-looking statements,
which speak only as of their dates. Except as otherwise
provided by law, Genomma undertakes no obligation to update
or revise any forward-
looking statements, whether as a result of new information,
future events or otherwise.
This communication does not constitute an offer to buy or
solicitation of an offer to sell any securities. No tender
offer for the shares of Prestige has commenced at this time.
In connection with the proposed transaction, Genomma may file
tender offer documents with the U.S. Securities and Exchange
Commission ("SEC"). Any definitive tender offer
documents will be mailed to stockholders of Prestige.
INVESTORS AND SECURITY HOLDERS OF PRESTIGE ARE URGED TO READ
THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN
THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
Investors and security holders of Prestige will be able to
obtain free copies of these documents (if and when available)
and other documents filed with the SEC by Genomma through the
web site maintained by the SEC at
http://www.sec.gov .
Contact:
Investor Relations In New York: Grayling USA, Lucía Domville
Tel: +52 (55) 5081 0000 Ext. 5106 Tel: +1 (646) 284-9416
E-mail: inversion@genommalab.comE-mail: genommalab@grayling.com
distributed by |